Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00082758 · ClinicalTrials.gov registry record · Phase 2
hu14.18-Interleukin-2 Fusion Protein in Treating Young Patients With Recurrent or Refractory Neuroblastoma
A Phase 2 study of Neuroblastoma, sponsored by Children's Oncology Group.
- Completed
- Registry status
- Phase 2
- Development phase
- 39
- Enrollment target
- 20
- Study locations
NCT00082758 is a Phase 2 study of Neuroblastoma that has completed, run by Children's Oncology Group. The registered enrollment target is 39 participants, below the 239-participant average among 94 other Neuroblastoma trials with a reported enrollment target (84% lower). The trial reports 20 study locations across 10 states.
The verdict
NCT00082758, a Phase 2 study of Neuroblastoma, has completed, sponsored by Children's Oncology Group.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 39 participants
- Enrollment target
- 20
- Study locations
Study Summary
RATIONALE: Biological therapies such as hu14.18-interleukin-2 fusion protein work in different ways to stimulate the immune system and stop tumor cells from growing. PURPOSE: This phase II trial is studying how well hu14.18-interleukin-2 fusion protein works in treating young patients with recurrent or refractory neuroblastoma.
Conditions Studied
Interventions
- BIOLOGICAL hu14.18-Interleukin-2 fusion protein
Study Locations (20)
California
- Childrens Hospital Los Angeles - Los Angeles
- Children's Hospital Central California - Madera
- Children's Hospital of Orange County - Orange
- Sutter Cancer Center - Sacramento
- UCSF Comprehensive Cancer Center - San Francisco
- Stanford Comprehensive Cancer Center - Stanford - Stanford
Florida
- University of Florida Shands Cancer Center - Gainesville
- Sacred Heart Cancer Center at Sacred Heart Hospital - Pensacola
- St. Joseph's Cancer Institute at St. Joseph's Hospital - Tampa
- Kaplan Cancer Center at St. Mary's Medical Center - West Palm Beach
Illinois
- Children's Memorial Hospital - Chicago - Chicago
- University of Chicago Cancer Research Center - Chicago
- Southern Illinois University School of Medicine - Springfield
Alabama
- Lurleen Wallace Comprehensive Cancer at University of Alabama - Birmingham - Birmingham
Arkansas
- Arkansas Cancer Research Center at University of Arkansas for Medical Sciences - Little Rock
Colorado
- Children's Hospital Cancer Center - Denver
District of Columbia
- Children's National Medical Center - Washington D.C.
Georgia
- MBCCOP - Medical College of Georgia Cancer Center - Augusta
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 39 participants |
| Start Date | 2005-08 |
| Est. Completion | 2012-05 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00082758
The ClinicalTrials.gov registry entry for NCT00082758 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 39 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 239-participant average among 94 other Neuroblastoma trials with a reported enrollment target (84% lower). The listed sponsor is Children's Oncology Group, which has 342 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Neuroblastoma appearing as the primary indexed condition, and to 1 intervention - of which hu14.18-Interleukin-2 fusion protein is the first listed.
NCT00082758 reports 20 study locations spanning 10 distinct geographic areas - top geographies include California, Florida, Illinois.
Frequently Asked Questions
What is clinical trial NCT00082758 about?
NCT00082758 is a clinical study titled "hu14.18-Interleukin-2 Fusion Protein in Treating Young Patients With Recurrent or Refractory Neuroblastoma". RATIONALE: Biological therapies such as hu14.18-interleukin-2 fusion protein work in different ways to stimulate the immune system and stop tumor cells from growing. PURPOSE: This phase II trial is studying how well hu14.18-interleukin-2 fusion protein works in treating young patients with recurren...
What is the current status of trial NCT00082758?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 39 participants. The study started on 2005-08. Estimated completion is 2012-05.
What conditions does trial NCT00082758 study?
This clinical trial studies the following conditions: Neuroblastoma.
What interventions are being tested in trial NCT00082758?
The interventions under investigation include: hu14.18-Interleukin-2 fusion protein (BIOLOGICAL).
Who is sponsoring clinical trial NCT00082758?
This trial is sponsored by Children's Oncology Group, which has 342 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00082758 being conducted?
This trial has 20 study locations across Alabama, Arkansas, California, Colorado, District of Columbia. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Neuroblastoma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Naxitamab for High-Risk Neuroblastoma Patients With Primary Refractory Disease or Incomplete Response to Salvage Treatment in Bone and/or Bone Marrow
RECRUITING · Phase 2
-
Tipifarnib and Naxitamab for Relapsed/Refractory Neuroblastoma
RECRUITING · Phase 2
-
A Study of Cabozantinib as a Maintenance Agent to Prevent Progression or Recurrence in High-Risk Pediatric Solid Tumors
RECRUITING · Phase 2
-
Iodine I 131 Metaiodobenzylguanidine in Treating Patients With Recurrent, Progressive, or Refractory Neuroblastoma or Malignant Pheochromocytoma or Paraganglioma
RECRUITING · Phase 2
-
Pediatric Precision Laboratory Advanced Neuroblastoma Therapy
RECRUITING · Phase 2
-
A Study of a Vaccine in Combination With β-glucan and GM-CSF in People With Neuroblastoma
RECRUITING · Phase 2
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.